Selected article for: "disease severity and early study"
Author: Gavriilaki, Eleni; Asteris, Panagiotis G.; Touloumenidou, Tasoula; Koravou, Evaggelia-Evdoxia; Koutra, Maria; Papayanni, Penelope Georgia; Karali, Vassiliki; Papalexandri, Apostolia; Varelas, Christos; Chatzopoulou, Fani; Chatzidimitriou, Maria; Chatzidimitriou, Dimitrios; Veleni, Anastasia; Grigoriadis, Savvas; Rapti, Evdoxia; Chloros, Diamantis; Kioumis, Ioannis; Kaimakamis, Evaggelos; Bitzani, Milly; Boumpas, Dimitrios; Tsantes, Argyris; Sotiropoulos, Damianos; Sakellari, Ioanna; Kalantzis, Ioannis G.; Parastatidis, Stefanos T.; Koopialipoor, Mohammadreza; Cavaleri, Liborio; Armaghani, Danial J.; Papadopoulou, Anastasia; Brodsky, Robert Alan; Kokoris, Styliani; Anagnostopoulos, Achilles
Title: Genetic justification of severe COVID-19 using a rigorous algorithm
  • Cord-id: ja6ydoed
  • Document date: 2021_4_13
    • ID: ja6ydoed
    Snippet: Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 vari
    Document: Recent studies suggest excessive complement activation in severe coronavirus disease-19 (COVID-19). The latter shares common characteristics with complement-mediated thrombotic microangiopathy (TMA). We hypothesized that genetic susceptibility would be evident in patients with severe COVID-19 (similar to TMA) and associated with disease severity. We analyzed genetic and clinical data from 97 patients hospitalized for COVID-19. Through targeted next-generation-sequencing we found an ADAMTS13 variant in 49 patients, along with two risk factor variants (C3, 21 patients; CFH,34 patients). 31 (32%) patients had a combination of these, which was independently associated with ICU hospitalization (p = 0.022). Analysis of almost infinite variant combinations showed that patients with rs1042580 in thrombomodulin and without rs800292 in complement factor H did not require ICU hospitalization. We also observed gender differences in ADAMTS13 and complement-related variants. In light of encouraging results by complement inhibitors, our study highlights a patient population that might benefit from early initiation of specific treatment.

    Search related documents:
    Co phrase search for related documents
    • abo blood group and acute respiratory syndrome: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21
    • abo blood group and adaptive innate: 1
    • acquire syndrome and acute ards respiratory distress syndrome: 1
    • acquire syndrome and acute respiratory syndrome: 1, 2, 3, 4, 5
    • action suggest mechanism and acute respiratory syndrome: 1, 2
    • acute ards respiratory distress syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22
    • acute ards respiratory distress syndrome and adaptive innate immunity: 1, 2, 3, 4, 5
    • acute ards respiratory distress syndrome and additional patient: 1, 2
    • acute ards respiratory distress syndrome and liver enzyme: 1, 2, 3, 4
    • acute respiratory syndrome and adaptive innate: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and adaptive innate immunity: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome and additional finding: 1
    • acute respiratory syndrome and additional patient: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome and liver enzyme: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • additional patient and liver enzyme: 1